Bone Morphogenetic Protein Receptor Type IA Human Recombinant ( BMPR1A Human )

Data sheet

Formulation

CD292 was lyophilized from a concentrated (1mg/ml) sterile solution containing 1X PBS.

Solubility

It is recommended to reconstitute the lyophilized ALK-3 in sterile PBS not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.

Purity

Greater than 90.0% as determined by(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

Description

BMPR1A Human Recombinant extracellular domain produced in baculovirus is a monomeric, glycosylated, Polypeptide chain fused with 6xHis tag at C-terminus and having a molecular mass of 23 kDa. The BMR1A is purified by proprietary chromatographic techniques

Protein Background

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, AC

Expression host

Insect Cells.

Synonyms

BMPR-1A, BMP-R1A, BMPR1A, BMR1A, CD292, CD-292, Serine/threonine-protein kinase receptor R5, SKR5, Activin receptor-like kinase 3, ALK-3, ACVRLK3, EC 2.7.11.30, CD292 antigen.

Reagent Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Stability

Lyophilized Bone Morphogenetic Protein Receptor 1A although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution BMPR1A should be stored at 4°C between 2-7 days and for future use below -18°C.For long term s

Biological Activity

Measured by its ability to inhibit recombinant human BMP-2 induced alkaline phosphatase production by C2C12 myogenic cells. The ED50 for this effect is typically 1-3 ug/ml in the presence of 500 ng/ml of recombinant human BMP-2 corresponding to a Specific